<DOC>
	<DOCNO>NCT02128269</DOCNO>
	<brief_summary>The primary purpose study evaluate safety tolerability intravenous ( IV ) ALXN1007 persistently antiphospholipid ( aPL ) -positive patient least 1 follow non-criteria manifestation APS : aPL-nephropathy , skin ulcer and/or thrombocytopenia .</brief_summary>
	<brief_title>Phase IIa Trial ALXN1007 Treatment Non-criteria Manifestations Antiphospholipid Syndrome</brief_title>
	<detailed_description>Enrollment discontinue early due recruitment difficulty . Initially enrolled patient complete study .</detailed_description>
	<mesh_term>Antiphospholipid Syndrome</mesh_term>
	<criteria>Patients persistent clinically significant aPL profile Patients least 1 follow noncriteria manifestation APS : 1. aPLnephropathy ( diagnosed kidney biopsy within 12 month Screening ) confirm base updated APS Classification Criteria recommendation , urine protein creatinine ratio &gt; 1.0 time Screening visit and/or 2 . Skin ulcer ( noninfected livedoid vasculitislike skin ulcer and/or large skin ulceration resemble pyoderma gangrenosum ) least 4 week prior Screening visit , diagnose physical examination , and/or 3 . Persistent active thrombocytopenia ( diagnosed platelet count &lt; 100 x 103/μL ≥20 x 103/μL [ SI : &lt; 100 x 109/L ≥ 20 x 109/L ] ) confirm time screening ( least 4 week previous test ) base updated APS Classification Criteria recommendation Patients spouse/partner childbearing potential must use highly effective contraception consist 2 form birth control ( least 1 must barrier method ) start Screening continue entire study . Patients aPLnephropathy must receive agree initiate ACE inhibitor angiotensin receptor blocker least 4 week prior initiation ALXN1007 treatment ; unless patient document intolerant . Patients receive oral corticosteroid must stable dose ≤ 10 mg/day prednisone equivalent dose another corticosteroid preparation least 4 week prior first dose ALXN1007 . Patients receive immunosuppressive medication ( include limit methotrexate , hydroxychloroquine , azathioprine , cyclosporine mycophenolate mofetil ) must stable dose least 4 week prior first dose ALXN1007 . Patients receive oral anticoagulant antiplatelet agent ( include limit aspirin ) must stable dos least 4 week prior first dose ALXN1007 . Patients must willing able give write informed consent comply study visit procedure . Patients meet ACR classification criterion systemic lupus erythematosus , systemic sclerosis systemic autoimmune disease Primary APS . Patients experience acute thrombosis Major Adverse Vascular Event ( MAVE ) within 12 week prior first administration ALXN1007 . Patients skin ulcer cause aPL positive DVT venous insufficiency Screening . Patients renal function status require chronic dialysis ( defined dialysis regular basis renal replacement therapy ) . Patients unresolved meningococcal disease know active bacterial , viral , fungal , mycobacterial infection . Patients receive IVIg treatment within 4 week prior first dose ALXN1007 . Patients receive course rituximab ( RITUXAN® ) therapy within 12 month prior first dose ALXN1007 evidence persistent depletion target lymphocyte population . Women pregnant nursing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Antiphospholipid ( aPL ) -positive</keyword>
	<keyword>Antiphospholid syndrome ( APS )</keyword>
</DOC>